Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.
Actionable alteration
Breast cancer
Classification
Gene expression
HER2
HER2-low
Heterogeneity
Mutation
Stratification
Transcriptome
Journal
Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844
Informations de publication
Date de publication:
29 08 2022
29 08 2022
Historique:
received:
14
03
2022
accepted:
10
08
2022
entrez:
29
8
2022
pubmed:
30
8
2022
medline:
1
9
2022
Statut:
epublish
Résumé
The "HER2-low" nomenclature identifies breast carcinomas (BCs) displaying a HER2 score of 1+/2+ in immunohistochemistry and lacking ERBB2 amplification. Whether HER2-low BCs (HLBCs) constitute a distinct entity is debated. We performed DNA and RNA high-throughput analysis on 99 HLBC samples (n = 34 cases with HER2 score 1+/HLBC-1, n = 15 cases with HER2 score 2+ and ERBB2 not amplified/HLBC-2N, and n = 50 cases with score 2+ and ERBB2 copy number in the equivocal range/HLBC-2E). We compared the mutation rates with data from 1317 samples in the Memorial Sloan-Kettering Cancer Center (MSKCC) BC cohort and gene expression data with those from an internal cohort of HER2-negative and HER2-positive BCs. The most represented mutations affected PIK3CA (31/99, 31%), GATA3 (18/99, 18%), TP53 (17/99, 17%), and ERBB2 (8/99, 8%, private to HLBC-2E). Tumor mutational burden was significantly higher in HLBC-1 compared to HLBC-2E/N (P = 0.04). Comparison of mutation spectra revealed that HLBCs were different from both HER2-negative and HER2-positive BCs, with HLBC-1 resembling more HER2-negative tumors and HLBC-2 mutationally related to HER2-addicted tumors. Potentially actionable alterations (annotated by using OncoKB/ESCAT classes) affected 52 patients. Intra-group gene expression revealed overlapping features between HLBC-1 and control HER2-negative BCs, whereas the HLBC-2E tumors showed the highest diversity overall. The RNA-based class discovery analysis unveiled four subsets of tumors with (i) lymphocyte activation, (ii) unique enrichment in HER2-related features, (iii) stromal remodeling alterations, and (iv) actionability of PIK3CA mutations (LAURA classification). HLBCs harbor distinct genomic features when compared with HER2-positive and HER2-negative BCs; however, differences across IHC classes were also unveiled thus dissecting the full picture of heterogeneity across HER2-low disease. The HLBC-2E category harbors most distinctive features, whereas HLBC-1 seems superimposable to HER2-negative disease. Further studies are needed to ascertain whether the four genomic-driver classes of the LAURA classification hold prognostic and/or predictive implications.
Sections du résumé
BACKGROUND
The "HER2-low" nomenclature identifies breast carcinomas (BCs) displaying a HER2 score of 1+/2+ in immunohistochemistry and lacking ERBB2 amplification. Whether HER2-low BCs (HLBCs) constitute a distinct entity is debated.
METHODS
We performed DNA and RNA high-throughput analysis on 99 HLBC samples (n = 34 cases with HER2 score 1+/HLBC-1, n = 15 cases with HER2 score 2+ and ERBB2 not amplified/HLBC-2N, and n = 50 cases with score 2+ and ERBB2 copy number in the equivocal range/HLBC-2E). We compared the mutation rates with data from 1317 samples in the Memorial Sloan-Kettering Cancer Center (MSKCC) BC cohort and gene expression data with those from an internal cohort of HER2-negative and HER2-positive BCs.
RESULTS
The most represented mutations affected PIK3CA (31/99, 31%), GATA3 (18/99, 18%), TP53 (17/99, 17%), and ERBB2 (8/99, 8%, private to HLBC-2E). Tumor mutational burden was significantly higher in HLBC-1 compared to HLBC-2E/N (P = 0.04). Comparison of mutation spectra revealed that HLBCs were different from both HER2-negative and HER2-positive BCs, with HLBC-1 resembling more HER2-negative tumors and HLBC-2 mutationally related to HER2-addicted tumors. Potentially actionable alterations (annotated by using OncoKB/ESCAT classes) affected 52 patients. Intra-group gene expression revealed overlapping features between HLBC-1 and control HER2-negative BCs, whereas the HLBC-2E tumors showed the highest diversity overall. The RNA-based class discovery analysis unveiled four subsets of tumors with (i) lymphocyte activation, (ii) unique enrichment in HER2-related features, (iii) stromal remodeling alterations, and (iv) actionability of PIK3CA mutations (LAURA classification).
CONCLUSIONS
HLBCs harbor distinct genomic features when compared with HER2-positive and HER2-negative BCs; however, differences across IHC classes were also unveiled thus dissecting the full picture of heterogeneity across HER2-low disease. The HLBC-2E category harbors most distinctive features, whereas HLBC-1 seems superimposable to HER2-negative disease. Further studies are needed to ascertain whether the four genomic-driver classes of the LAURA classification hold prognostic and/or predictive implications.
Identifiants
pubmed: 36038884
doi: 10.1186/s13073-022-01104-z
pii: 10.1186/s13073-022-01104-z
pmc: PMC9426037
doi:
Substances chimiques
Biomarkers, Tumor
0
RNA
63231-63-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
98Informations de copyright
© 2022. The Author(s).
Références
Ann Oncol. 2021 Feb;32(2):208-217
pubmed: 33246021
J Immunother Cancer. 2017 Feb 21;5:18
pubmed: 28239471
Ann Oncol. 2018 Sep 1;29(9):1895-1902
pubmed: 30137196
J Clin Oncol. 2020 Jun 10;38(17):1951-1962
pubmed: 32330069
Am J Hum Genet. 2017 Feb 2;100(2):267-280
pubmed: 28132688
J Clin Oncol. 2020 Jun 10;38(17):1887-1896
pubmed: 32058843
NPJ Breast Cancer. 2021 Jan 4;7(1):1
pubmed: 33397968
Semin Cancer Biol. 2021 Jul;72:123-135
pubmed: 32112814
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
NPJ Precis Oncol. 2022 Mar 8;6(1):15
pubmed: 35260767
Cancer Res. 2022 Jan 1;82(1):25-35
pubmed: 34711612
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669
Cancer Cell. 2018 Sep 10;34(3):427-438.e6
pubmed: 30205045
Am J Surg Pathol. 2018 Sep;42(9):1190-1200
pubmed: 29975246
Endocr Relat Cancer. 2006 Mar;13(1):39-49
pubmed: 16601278
JAMA Netw Open. 2021 Nov 1;4(11):e2133132
pubmed: 34739066
J Clin Oncol. 2020 Apr 20;38(12):1346-1366
pubmed: 31928404
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Cell Rep. 2021 Mar 9;34(10):108822
pubmed: 33691110
Lancet Oncol. 2019 Aug;20(8):1124-1135
pubmed: 31257177
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
Front Oncol. 2021 Apr 20;11:663419
pubmed: 33959510
BMC Bioinformatics. 2010 Jul 02;11:367
pubmed: 20598126
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Ann Oncol. 2019 Mar 1;30(3):365-373
pubmed: 30715161
Cancers (Basel). 2021 Jun 05;13(11):
pubmed: 34198891
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
J Clin Oncol. 2009 Mar 10;27(8):1160-7
pubmed: 19204204